Balance Sheet
Accumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Shares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

Aimei Health Technology (AFJK) Shares Outstanding (2023 - 2025)

Aimei Health Technology (AFJK) has 3 years of Shares Outstanding data on record, last reported at $2.1 million in Q3 2025.

  • On a quarterly basis, Shares Outstanding changed 0.0% to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a 0.0% change, with the full-year FY2024 number at $2.1 million, changed 0.0% from a year prior.
  • Shares Outstanding reached $2.1 million in Q3 2025 per AFJK's latest filing, roughly flat from $2.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for AFJK hit a ceiling of $2.1 million in Q4 2023 and a floor of $2.1 million in Q4 2023.
  • A 3-year average of $2.1 million and a median of $2.1 million in 2023 define the central range for Shares Outstanding.
  • On a YoY basis, Shares Outstanding climbed as much as 0.0% in 2024 and fell as far as 0.0% in 2024.
  • Tracing AFJK's Shares Outstanding over 3 years: stood at $2.1 million in 2023, then changed by 0.0% to $2.1 million in 2024, then changed by 0.0% to $2.1 million in 2025.
  • Business Quant data shows Shares Outstanding for AFJK at $2.1 million in Q3 2025, $2.1 million in Q2 2025, and $2.1 million in Q1 2025.